Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH-Reference-Cited by-同舟云学术

Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH

Published:2010-01-30 Issue:7 Volume:45 Page:750-757
ISSN:0944-1174
Container-title:Journal of Gastroenterology
language:en
Short-container-title:J Gastroenterol

Author:

Kimura Yuki,Hyogo Hideyuki,Yamagishi Sho-ichi,Takeuchi Masayoshi,Ishitobi Tomokazu,Nabeshima Yoshitaka,Arihiro Koji,Chayama Kazuaki

Publisher

Springer Science and Business Media LLC

Subject

Gastroenterology

Link

http://link.springer.com/content/pdf/10.1007/s00535-010-0203-y.pdf

Reference41 articles.

1. Teli MR, James OF, Burt AD, Bennett MK, Day CP. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology. 1995;22:1714–9.

2. Dam-Larsen S, Franzmann M, Andersen IB, Christoffersen P, Jensen LB, Sørensen TI, et al. Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut. 2004;53:750–5.

3. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116:1413–9.

4. James O, Day C. Non-alcoholic steatohepatitis: another disease of affluence. Lancet. 1999;353:1634–6.

5. Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, et al. NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology. 2002;35:373–9.

Cited by 143 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Potential therapeutic strategies for MASH: from preclinical to clinical development;Life Metabolism;2024-07-06

2. Untargeted Lipidomics Analysis in Metabolic Dysfunction-Associated Steatohepatitis Associated with Morbid Obesity;2024-07-01

3. Review of current and new drugs for the treatment of metabolic-associated fatty liver disease;Hepatology International;2024-06-08

4. Statins in Chronic Liver Disease: Review of the Literature and Future Role;Seminars in Liver Disease;2024-05

5. A Systematic Review of Statins for the Treatment of Nonalcoholic Steatohepatitis: Safety, Efficacy, and Mechanism of Action;Molecules;2024-04-19